



Original Research

# Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US



Marios K. Georgakis<sup>a</sup>, Paraskevi Panagopoulou<sup>a,b</sup>,  
Paraskevi Papatoma<sup>a</sup>, Athanasios Tragiannidis<sup>c</sup>, Anton Ryzhov<sup>d</sup>,  
Snezana Zivkovic-Perisic<sup>e</sup>, Sultan Eser<sup>f</sup>, Łukasz Taraszkievicz<sup>g</sup>,  
Mario Sekerija<sup>h,i</sup>, Tina Žagar<sup>j</sup>, Luis Antunes<sup>k</sup>, Anna Zborovskaya<sup>l</sup>,  
Joana Bastos<sup>m</sup>, Margareta Florea<sup>n</sup>, Daniela Coza<sup>o</sup>, Anna Demetriou<sup>p</sup>,  
Domenic Agius<sup>q</sup>, Rajko M. Strahinja<sup>r</sup>, Georgios Sfakianos<sup>s</sup>,  
Ioannis Nikas<sup>t</sup>, Sofia Kosmidis<sup>u</sup>, Evangelia Razis<sup>v</sup>,  
Apostolos Pourtsidis<sup>w</sup>, Maria Kantzanou<sup>a</sup>, Nick Dessypris<sup>a</sup>,  
Eleni Th. Petridou<sup>a,x,\*</sup>

<sup>a</sup> Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece

<sup>b</sup> Fourth Department of Pediatrics, Medical School, General Hospital “Papageorgiou”, Aristotle University of Thessaloniki, Thessaloniki, Greece

<sup>c</sup> Second Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Greece

<sup>d</sup> National Cancer Registry of Ukraine, National Institute of Cancer, Kyiv, Ukraine

<sup>e</sup> Institute of Public Health of Serbia, Department for NCD Prevention and Control, Cancer Registry for Central Serbia, Belgrade, Serbia

<sup>f</sup> Izmir Cancer Registry, Izmir Hub, Izmir & Hacettepe University Institute of Public Health, Ankara, Turkey

<sup>g</sup> Greater Poland Cancer Registry, Department of Cancer Prevention and Epidemiology, Greater Poland Cancer Center, Poznan, Poland

<sup>h</sup> Croatian National Cancer Registry, Croatian Institute of Public Health, Zagreb, Croatia

<sup>i</sup> School of Public Health “Andrija Stampar”, School of Medicine, University of Zagreb, Zagreb, Croatia

<sup>j</sup> Cancer Registry of Republic of Slovenia, Institute of Oncology, Ljubljana, Slovenia

<sup>k</sup> North Region Cancer Registry of Portugal (RORENO), Portuguese Oncology Institute of Porto, Portugal

<sup>l</sup> Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Childhood Cancer Subregistry of Belarus, Minsk, Belarus

<sup>m</sup> Central Region Cancer Registry of Portugal (ROR-Centro), Portuguese Oncology Institute of Coimbra, Portugal

<sup>n</sup> Regional Cancer Registry of Iasi, National Institute of Public Health, Iasi, Romania

<sup>o</sup> Regional Cancer Registry of Cluj, Oncological Institute “Ion Chiricuta”, Cluj-Napoca, Romania

<sup>p</sup> Cyprus Cancer Registry-Health Monitoring Unit, Ministry of Health, Nicosia, Cyprus

\* Corresponding author: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Str, Athens 11527, Greece. Fax: +30 210 7462105.

E-mail address: [epetrid@med.uoa.gr](mailto:epetrid@med.uoa.gr) (E.Th. Petridou).

<sup>q</sup> Malta National Cancer Registry, Department of Health Information and Research, Malta<sup>r</sup> Institute of Public Health, Center for Disease Prevention and Control, Department for Epidemiology of NCDs, Cancer Registry, Podgorica, Montenegro<sup>s</sup> Department of Neurosurgery, “Aghia Sophia” Children’s Hospital, Athens, Greece<sup>t</sup> Imaging Department, “Aghia Sophia” Children’s Hospital of Athens, Athens, Greece<sup>u</sup> Radiotherapy-Oncology Department, Hygeia Hospital, Athens, Greece<sup>v</sup> Third Department of Internal Medicine-Oncology, Hygeia Hospital, Athens, Greece<sup>w</sup> Department of Pediatric Hematology-Oncology, “Pan. & Agl. Kyriakou” Children’s Hospital, Athens, Greece<sup>x</sup> Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden

Received 13 July 2017; received in revised form 23 August 2017; accepted 25 August 2017

## KEYWORDS

Adolescents and young adults;  
Central nervous system tumours;  
Brain tumours;  
Cancer registration;  
Incidence;  
Epidemiology

**Abstract** *Aim:* To present incidence of central nervous system (CNS) tumours among adolescents and young adults (AYAs; 15–39 years) derived from registries of Southern and Eastern Europe (SEE) in comparison to the Surveillance, Epidemiology and End Results (SEER), US and explore changes due to etiological parameters or registration improvement via evaluating time trends.

*Methods:* Diagnoses of 11,438 incident malignant CNS tumours in AYAs (1990–2014) were retrieved from 14 collaborating SEE cancer registries and 13,573 from the publicly available SEER database (1990–2012). Age-adjusted incidence rates (AIRs) were calculated; Poisson and joinpoint regression analyses were performed for temporal trends.

*Results:* The overall AIR of malignant CNS tumours among AYAs was higher in SEE (28.1/million) compared to SEER (24.7/million). Astrocytomas comprised almost half of the cases in both regions, albeit the higher proportion of unspecified cases in SEE registries (30% versus 2.5% in SEER). Similar were the age and gender distributions across SEE and SEER with a male-to-female ratio of 1.3 and an overall increase of incidence by age. Increasing temporal trends in incidence were documented in four SEE registries (Greater Poland, Portugal North, Turkey-Izmir and Ukraine) versus an annual decrease in Croatia (–2.5%) and a rather stable rate in SEER (–0.3%).

*Conclusion:* This first report on descriptive epidemiology of AYAs malignant CNS tumours in the SEE area shows higher incidence rates as compared to the United States of America and variable temporal trends that may be linked to registration improvements. Hence, it emphasises the need for optimisation of cancer registration processes, as to enable the in-depth evaluation of the observed patterns by disease subtype.

© 2017 Elsevier Ltd. All rights reserved.

## 1. Introduction

Central nervous system (CNS) tumours comprise a heterogeneous group of malignancies of variable behaviour and histology arising from the cerebral parenchyma or the surrounding structures. Across the whole age spectrum, the global annual incidence rate of brain tumours (malignant and non-malignant) is 10.8 cases per 100,000 individuals, according to a recent meta-analysis [1], whereas the GLOBOCAN project using nationwide data from 184 countries estimated the annual incidence of malignant-only CNS tumours to be 3.4 per 100,000 individuals [2]. Increasing temporal trends have been reported especially in the previous decades, which have been explained by the diagnostic advances in neuroimaging technology and improvements in disease

classification [3]. Although CNS tumours are traditionally considered a fatal malignancy and are included among the top 10 causes of death due to cancer worldwide, their prognosis has considerably improved over the last decades possibly because of the prompt detection, the optimisation of treatment protocols including the introduction of temozolomide and the advances in neurosurgical procedures [4–6].

CNS tumours are more common among males [1,2] and their age distribution markedly increases with age reaching its peak incidence in individuals >65 years [2], although variations are noted dependent on the histological subtype under study [7]. CNS tumours constitute the second most common cancer in childhood (0–14 years) and the third most common malignancy in the special age group of adolescents and young adults (AYAs; 15–39

Download English Version:

<https://daneshyari.com/en/article/8440696>

Download Persian Version:

<https://daneshyari.com/article/8440696>

[Daneshyari.com](https://daneshyari.com)